Antiviral treatment of chronic hepatitis B patients with renal insufficiency
10.3760/cma.j.issn.1674-2397.2020.01.016
- VernacularTitle:慢性乙型肝炎合并肾功能不全患者抗病毒治疗研究进展
- Author:
Jueqing GU
1
;
Hongyu JIA
;
Xiaoli ZHANG
;
Chanyuan YE
;
Yida YANG
Author Information
1. 浙江大学医学院附属第一医院传染病诊治国家重点实验室、国家感染性疾病临床医学研究中心、感染性疾病诊治协同创新中心，杭州 310003
- From:
Chinese Journal of Clinical Infectious Diseases
2020;13(1):75-80
- CountryChina
- Language:Chinese
-
Abstract:
Chronic hepatitis B (CHB) is an infectious disease characterized by liver damage, which can progress to liver fibrosis, cirrhosis, liver failure or liver cancer, threatening the life of patients. CHB patients are prone to be complicated with hepatitis B virus-associated glomerulonephritis and other kidney diseases, therefore the renal safety should be fully considered in the antiviral treatment of CHB patients. According to current guidelines, telbivudine, entecavir or tenofovir alafenamide are recommended for CHB patients with renal insufficiency or potential renal injury, but each has its advantages and disadvantages. How to carry out antiviral treatment in CHB patients with renal impairment deserves our attention. At the same time, the renal function should be monitored regularly in the course of antiviral treatment to identify the damage of renal function in the early stage. This article reviews the causes of renal dysfunction in CHB patients, the risk of kidney damage during the antiviral treatment, the choices of antiviral therapy and the monitoring of renal function in the patients.
